Revvity’s share price has risen over the past year, yet its longer term record is weaker and the valuation tools do not quite line up. The Discounted Cash Flow (DCF) intrinsic value estimate points to a discount to current pricing, while earnings based multiples signal a richer valuation.

• Over 5 years, Revvity’s shareholders have seen the stock decline 38.6%, which makes the current valuation more sensitive to how the next phase of the business plays out.
• Expectations for future cash flow generation can support the DCF view of upside, but any disappointment in growth or margins may reinforce the caution implied by the richer market multiples.
• On Simply Wall St’s broader checks, Revvity scores 3 out of 6 on value, which points to a mixed picture rather than a clear bargain or clear overvaluation.

The stock’s next move may depend on whether the DCF style intrinsic value or the earnings multiple view turns out to be closer to how the market prices Revvity over time.

Is Revvity a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach here is based on projected free cash the business could return to shareholders over time.

For Revvity, the model starts from latest twelve month free cash flow of about $486.9 million and uses that as the baseline for cash generation projections over the coming years. On these projections, the 2 Stage Free Cash Flow to Equity model points to an estimated intrinsic value of about $145 per share. That figure is above the current market price, which indicates that the cash flow outlook embedded in the DCF is more optimistic than what the market is currently pricing in.

The DCF output indicates that Revvity is valued at a 22.0% discount to this intrinsic value estimate. This gap highlights how much importance an investor might place on the company’s ability to deliver the forecast cash flows and sustain margins over time.

On this cash flow view, Revvity stock currently appears undervalued.

Our Discounted Cash Flow (DCF) analysis suggests Revvity is undervalued by 22.0%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Does Revvity Look Pricey on Earnings?

The P/E ratio suits Revvity because earnings are a core focus for investors in established Life Sciences companies. Revvity currently trades on a P/E of about 52.9x, which sits above the Life Sciences industry average of roughly 37.1x and below the peer group average of about 63.7x. So the stock is priced richer than the broader industry but not at the very top end of its closer peer set.

On Simply Wall St’s model, the fair P/E for Revvity is estimated at about 25.0x once factors like growth prospects, profitability, size and risk are taken into account. The current 52.9x P/E is therefore more than double this fair ratio, which suggests that investors are paying a premium for each dollar of current earnings compared to what the model indicates as a reasonable anchor.

On this earnings multiple view, Revvity stock currently screens as overvalued.

The Revvity Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Revvity pick up where this valuation gap leaves off. They set out clear scenarios for what kind of future growth, margins and earnings path would need to occur for the stock to be worth materially more or materially less than today’s price. Each narrative links its number to a specific view on how Revvity's growth, profitability and risks could evolve, which you can revisit as fresh information becomes available.

Community views on Revvity sit far apart, with one side focusing on software and diagnostics momentum and the other on policy and funding risks.

Bull case: roughly fairly valued

"Accelerating adoption of Revvity's high-growth software solutions (30%+ organic growth in Signals, record orders, high ARR and net retention), driven by pharma/biotech spending on digital transformation, supports sustained revenue growth and recurring, higher-margin streams…"

Bear case: 26% overvalued

"Accelerating regulatory and reimbursement shifts in China, such as the DRG (diagnosis-related groups) debundling policy, are causing a sustained, high-teen percentage decline in Revvity's high-margin immunodiagnostics business in the region, which is expected to reduce total company organic revenue growth and operating margins in the near and medium term…"

Do you think there's more to the story for Revvity? Head over to our Community to see what others are saying!

The Bottom Line

Revvity sits in the middle ground. The Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside from current levels, while the P/E multiple suggests the stock is overvalued on today’s earnings. That gap mainly comes down to how you weigh future cash flow delivery against what the market already prices in for growth and margins. The key question is whether Revvity can sustain the cash generation and profitability that the intrinsic value view assumes, or whether the richer earnings multiple is already capturing that optimism.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.